Industry Reports

In early 2026, the White House struck a series of tariff and pricing deals with major pharma firms, linking lower prices for GLP‑1 and other drugs to tariff relief and new distribution channels. Explore how these arrangements are reshaping U.S. pharma pricing, access and global spillovers.

In 2026, GSK, Amgen and other large pharma players restarted the M&A engine with targeted deals in immunology and oncology, signalling a shift toward science‑driven, portfolio‑balancing acquisitions. Explore how this new M&A cycle is reshaping the global pharma landscape.

Global pharma in Q1‑2026 is defined by pricing shocks in the US and Europe and a powerful growth shift to Asia. Explore how policy, margins, M&A and regional strategies are reshaping the pharmaceutical industry.

The global pharmaceutical industry is entering a pivotal phase in obesity therapeutics as companies accelerate the transition from injectable GLP-1 drugs to oral weight-loss treatments, a shift expected to significantly expand patient access, alter reimbursement dynamics, and intensify competitive...

Over more than ten years working in healthcare, medical manufacturing, and life sciences, it’s clear how much the industry has developed and adapted. One of the biggest shifts has been the focus on sustainability. What used to be a...

Bringing a pharmaceutical product to market is hard work. Pre-market regulatory requirements in the United States and the European Union are well established and generally well understood by experienced development teams. And it still years and millions of dollars...

Asia-Pacific’s biotechnology landscape is not just growing it is transforming. In 2026, the region stands at a unique crossroads where scientific ambition meets real-world demands. This year will test the industry’s resilience, shape global health priorities, and redefine how...